ABBOTINDIA:NSE-Abbott India Limited (INR)

COMMON STOCK | Drug Manufacturers-General | NSE

Last Closing Price

INR 20,208.95

Change

+12.75 (+0.06)%

Market Cap

INR 432.55B

Volume

5.49K

Avg Analyst Target

INR 20,733.20 (+2.59%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

ABBOTINDIA Stock Forecast & Price:
Based on the Abbott India Limited stock forecasts from 3 analysts, the average analyst target price for Abbott India Limited is INR 20,733.20 over the next 12 months. Abbott India Limited’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Abbott India Limited is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, Abbott India Limited’s stock price was INR 20,208.95. Abbott India Limited’s stock price has changed by -0.14% over the past week, +4.55% over the past month and +7.72% over the last year.

About Abbott India Limited (ABBOTINDIA:NSE)

Abbott India Limited operates as a pharmaceutical company in India. It offers pharmaceutical products for various therapeutic areas, such as women's health, gastroenterology, metabolic, central nervous system, pain management, pre-term labor, vitamins, insomnia, vaccines, consume ...Read More

Company Website : https://www.abbott.co.in

Address : Godrej BKC, Mumbai, India, 400051

Employees : 3,597

Fiscal Year End : March

Currency: INR

Country : India

Technical Indicators

Beta : 0.03

52 Week High : 20,900.80

52 Week Low : 15,415.83

200 Day Moving Average : 18,367.24

50 Day Moving Average : 19,183.87

Shares Held By Insiders : 74.99%

Shares Held by Institutions : 7.22%

Dividend Yield : 0.72%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-12-07 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CIPLA:NSE Cipla Limited

-4.30 (-0.39%)

 INR896.29B 34.92 18.21
GLAND:NSE Gland Pharma Limited

-34.50 (-1.99%)

 INR287.97B 30.57 16.49
GLAXO:NSE GlaxoSmithKline Pharmaceutical..

+10.90 (+0.82%)

 INR225.34B 57.19 24.49
PFIZER:NSE Pfizer Limited

-25.65 (-0.56%)

 INR209.91B 34.23 20.72
SANOFI:NSE Sanofi India Limited

-6.50 (-0.11%)

 INR131.63B 22.69 14.75
MARKSANS:NSE Marksans Pharma Limited

-0.20 (-0.31%)

 INR24.39B 12.31 6.32
TTKHLTCARE:NSE TTK Healthcare Limited

-7.10 (-0.71%)

 INR13.19B 58.24 6.61
NGLFINE:NSE NGL Fine-Chem Limited

+3.10 (+0.19%)

 INR10.26B 48.84 23.21
KOPRAN:NSE Kopran Limited

-2.25 (-1.40%)

 INR8.15B 15.51 10.58
SMSPHARMA:NSE SMS Pharmaceuticals Limited

-0.25 (-0.30%)

 INR7.17B 28.22 12.45

ETFs Containing ABBOTINDIA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.71% 70% C- 54% F
Dividend Return 0.67% 44% F 40% F
Total Return 4.38% 70% C- 53% F
Trailing 12 Months  
Capital Gain 6.74% 70% C- 52% F
Dividend Return 0.69% 44% F 41% F
Total Return 7.43% 70% C- 52% F
Trailing 5 Years  
Capital Gain 258.11% 100% A+ 93% A
Dividend Return 9.36% 75% C 86% B
Total Return 267.47% 100% A+ 93% A
Average Annual (5 Year Horizon)  
Capital Gain 32.94% 70% C- 71% C-
Dividend Return 0.85% 78% C+ 58% F
Total Return 33.79% 70% C- 70% C-
Risk Return Profile  
Volatility (Standard Deviation) 35.18% 50% F 76% C
Risk Adjusted Return 96.02% 100% A+ 98% A+
Market Capitalization 432.55B 91% A- 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 48.73 36% F 21% F
Price/Book Ratio 15.80 9% F 5% F
Price / Cash Flow Ratio 45.64 18% F 18% F
EV/EBITDA 32.27 9% F 14% F
Management Effectiveness  
Return on Equity 34.42% 91% A- 93% A
Return on Invested Capital 27.32% 100% A+ 93% A
Return on Assets 17.77% 100% A+ 97% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield 0.72% 44% F 44% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.03 100% A+ 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.